Butterfly Network, Inc. announced the FDA clearance of its next-generation handheld point-of-care ultrasound (POCUS) system, Butterfly iQ3. The new device is the company?s third iteration of the world?s first semiconductor-based single-probe, whole-body ultrasound system. Butterfly iQ3 features a brand-new ergonomic design and will deliver double the data processing speed for optimized image resolution, sensitivity and penetration, as well as faster 3D capabilities to power novel, automated image capture modes: iQ Slice and iQ Fan.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.844 USD | +8.37% | +16.48% | -22.25% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-22.25% | 162M | |
+8.82% | 219B | |
+7.35% | 183B | |
+11.19% | 133B | |
+25.54% | 108B | |
+0.27% | 63.06B | |
+13.33% | 52.02B | |
+3.96% | 48.2B | |
+0.26% | 40.37B | |
+13.57% | 39.35B |
- Stock Market
- Equities
- BFLY Stock
- News Butterfly Network, Inc.
- Butterfly Network Announces Fda Clearance of Its Next-Generation Handheld Ultrasound System, Butterfly Iq3